Floatz logo

15 assets in Pulmonary Fibrosis

Therapeutic assets addressing Pulmonary Fibrosis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Acetylcysteine
Pulmonary Fibrosis
Boehringer IngelheimP3BB (70)
Nintedanib
Pulmonary Fibrosis
Boehringer IngelheimP3BB (67)
Admilparant
Pulmonary Fibrosis
Bristol-Myers SquibbP3BB (66)
Pirfenidone
Pulmonary Fibrosis
Boehringer IngelheimP2BB (66)
[68ga]cbp8
Pulmonary Fibrosis
Peter CaravanP2B (60)
Nerandomilast
Pulmonary Fibrosis
Boehringer IngelheimP3B (60)
XENON
Pulmonary Fibrosis
Duke UniversityP2B (59)
Sirolimus
Pulmonary Fibrosis
University of ChicagoP2/3B (57)
Uniprost
Pulmonary Fibrosis
United TherapeuticsP3B (57)
ap01
Pulmonary Fibrosis
Avalyn Pharma Inc.P2CCC (53)
bi 1839100
Pulmonary Fibrosis
Boehringer IngelheimP2CCC (53)
Suplatast Tosylate
Pulmonary Fibrosis
Melius Pharma ABP2CCC (53)
Gallium-68 Labelled Fap-2286
Pulmonary Fibrosis
Thomas HopeP1CC (46)
Fapi-46
Pulmonary Fibrosis
University of California, Los AngelesEarly P1C (39)
Env-101
Pulmonary Fibrosis
Endeavor Biomedicines, Inc.P2NR ()